Skip to main content
. Author manuscript; available in PMC: 2016 May 18.
Published in final edited form as: Oncogene. 2015 Jul 6;35(9):1143–1152. doi: 10.1038/onc.2015.169

Figure 5. LRIG1 decreases growth of luminal breast cancer cells.

Figure 5

A. Using TCGA-curated luminal breast cancer datasets, the RPPA protein score for ESR1 (ERα) was plotted for those tumors with high LRIG1, NRDP1, and NEDD4 mRNA expression as compared to the remaining luminal tumors. Midlines represent average, whiskers indicate S.D. Analysis was performed on cBioPortal.org.

B. Western analysis of whole cell lysates harvested form cells cultured 24 h in 10% serum with fulvestrant (1μM) or equal volume of DMSO.

C. LRIG1 transcripts were measured in whole cell RNA harvested from cells cultured 24 h in 10% serum with fulvestrant (1μM) or DMSO. Values represent average relative mRNA levels (± S.D.), N = 3, each analyzed in triplicate. Student’s T-test.

D. LRIG1 transcripts were measured in whole tumor RNA harvested from MCF7 and MDA-MB-361 xenografts treated for 7 days with fulvestrant or vehicle. Values represent average relative mRNA levels (± S.D.), N = 4, each analyzed in triplicate. Student’s T-test.

E. Western analysis of whole cell lysates harvested form cells cultured 24 h in 10% charcoal stripped serum with estrogen (20 pM) or equal volume ethanol. Values represent average relative mRNA levels (± S.D.), N = 3, each analyzed in triplicate. Student’s T-test.